Medication Modification Equivalent for Virtual and In-Person Psychiatric Visits

, ,

Mental health leads with 36% of all outpatient visits and 39% of all telehealth services. What effect does this have on psychiatric practice?


Over the past 3 years, the worldwide spread of COVID-19 has created disruption and change in nearly all aspects of our lives. For mental health services, the transition to virtual rather than in-person care has been generally successful. At its peak in March through August 2020, 40% of all outpatient visits were provided virtually by mental health providers, compared to only 11% by other providers.1 After removal of most limitations, mental health still leads, accounting for 36% of all outpatient visits and 39% of all telehealth services.1

COVID-19 accelerated a process that was already in effect. Prior to the pandemic, telehealth was used predominantly to provide care in underserved settings (eg, rural areas) and accounted for less than 10% of all visits.2 Its use was increasing despite concerns by leading psychiatrists that virtual visits deteriorate the doctor-patient relationship that is so important in the practice of psychiatry.3-5 Two years after the lockdown began, telehealth visits account for more than 25% of all medical interactions.6

Most of the studies examining the adequacy of telepsychiatry have examined subjective impressions of clinicians and patients. Patient satisfaction is generally good,7 but some patients report a lesser connection to their clinician.8 Provider satisfaction is more mixed with concerns about quality of services, patient perceptions, and technological issues.7 Mental health providers generally are more positive regarding telehealth than either primary care or specialists and generally prefer video telehealth over voice only.9 Increased access and convenience are generally sited as benefits of telepsychiatry.10 Pre-COVID-19 studies comparing in-person care with telepsychiatry generally showed that remote treatment was comparable or superior (in terms of rating-scale improvement of target symptoms) to in-person treatment.7

However, participants in these pre-COVID-19 studies chose to be involved in a telehealth study. Patients and clinicians had telehealth forced upon them through the COVID-19 shutdowns. That difference is a potentially important variable.

Medication change in treatment is generally driven by patient complaints or clinician observations of patients’ presentations.11 It can serve as an objective measure of clinician involvement in the evaluation process.12 We performed a quality assurance retrospective chart review examining the objective outcome of medication intervention comparing individuals who attended the same clinic remotely or in person. The study was performed after the shutdown restrictions were slowly being lifted in 2021 and 2022, and some patients were transitioning back to in-person visits.

We examined 280 visits among 173 patients. The majority of these visits were telehealth (224, or 80%). There were 115 women, 57 men, and 1 unspecified gender. The primary diagnoses were major depressive disorder, generalized anxiety disorder, posttraumatic stress disorder, and attention-deficit/hyperactivity disorder. There were 96 medication changes among the telehealth visits (42.8%) and 21 among the in-person visits (37.5%). The difference was not significant (z = -1.4, P = 0.16), suggesting that clinician assessments of the need for altering treatment are the same.

Telepsychiatry appears to be here to stay. Additional studies need to be done to confirm equivalence of remote versus in-person outcomes. However, the early results of our study and the current literature suggest that use of telehealth for mental health conditions is a reasonable option.

Dr Mumtazis a PGY-1 resident in the department of psychiatry and behavioral sciences at the University of Louisville School of Medicine in Louisville, Kentucky. Dr Adigun is research coordinator at University of Louisville Division of Infectious Diseases. Dr El-Mallakh is a professor in the department of psychiatry and behavioral sciences and director of the Mood Disorders Research Program at the University of Louisville School of Medicine in Louisville, Kentucky.

Disclosures: Dr El-Mallakh is a speaker for Idorsia, Indivior, Intracellular Therapies, Janssen, Lundbeck, Noven, Otsuka, Sunovion, and Teva.


1. Lo J, Rae M, Amin K, et al. Telehealth has played an outsized role meeting mental health needs during the COVID-19 pandemic. Kaiser Family Foundation. March 15, 2022. Accessed September 21, 2022.

2. Mann DM, Chen J, Chunara R, et al. COVID-19 transforms health care through telemedicine: evidence from the field. J Am Med Inform Assoc. 2020;27(7):1132-1135.

3. Tasman A. Presidential address: the doctor‐patient relationship. Am J Psychiatry. 2000;157(11):1762-1768.

4. May C, Gask L, Atkinson T, et al. Resisting and promoting new technologies in clinical practice: the case of telepsychiatry. Soc Sci Med. 2001;52(12):1889-1901.

5. Wagnild G, Leenknecht C, Sauher J. Psychiatrists’ satisfaction with telepsychiatry. Telemed J E Health. 2006;12(5):546-551.

6. Karimi M, Lee EC, Couture SJ, et al. National trends in telehealth use in 2021: disparities in utilization and audio vs. video services. (Research Report No. HP-2022-04). Office of the Assistant Secretary for Planning and Evaluation, US Department of Health and Human Services. February 2022. Accessed September 21, 2022.

7. Hubley S, Lynch SB, Schneck C, et al. Review of key telepsychiatry outcomes. World J Psychiatry. 2016;6(2):269-282.

8. Urness D, Wass M, Gordon A, et al. Client acceptability and quality of life – telepsychiatry compared to in-person consultation. J Telemed Telecare. 2006;12(5):251-254.

9. Connolly SL, Miller CJ, Gifford AL, Charness ME. Perceptions and use of telehealth among mental health, primary, and specialty care clinicians during the COVID-19 pandemic. JAMA Netw Open. 2022;5(6):e2216401.

10. Parikh SV, Taubman DS, Grambeau M, et al. Going virtual during a pandemic: an academic psychiatry department's experience with telepsychiatry. Psychopharmacol Bull. 2021;51(1):59-68.

11. Hodgkin D, Stewart MT, Merrick EL, et al. Prevalence and predictors of physician recommendations for medication adjustment in bipolar disorder treatment. J Affect Disord.2018;238:666-673.

12. Alleyne JE, Bashir AS, Birdwhistell ML, et al. The effect of teaching clinics on prescribing practices. Acad Psychiatry. 2015;40(2):317-320.